This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants
and nurse practitioners involved in the care of patients with chronic liver disease.
|
The goal of this program is to improve healthcare providers competency in understanding the long-term effects and potential
liver related complications of chronic liver diseases, focusing on HBV. The program will also provide education on management options and outcomes of treatment.
|
|
|
After completing this activity, the participants should be better able to:
- Review the most recent advances in the management of HBV
- Identify potential therapeutic modalities in HBV and HCV
- Describe the importance of diagnosis and treatment of hepatic encephalopathy and hepatocellular carcinoma
|
This activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME)
through the sponsorship of Postgraduate Institute for Medicine. Postgraduate Institute for Medicine
is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release - November 18, 2008
Expiration - November 18, 2009
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to
control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by
PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its
learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty and planners/managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner
have with commercial interest related to the content of this CME activity:
Dr. Willis Maddrey has received consulting fees from the following commercial entities: Bristol-Myers Squibb
Dr. Eugene Schiff has received consulting fees from the following commercial entities: Bristol-Myers Squibb, Salix Pharmaceuticals, Vertex Pharmaceuticals
Dr. Luis Balart has received consulting fees from the following commercial entities: Schering-Plough, Roche Labs, Intermune, SciClone
Dr. Bruce Bacon has received research support from Bristol-Myers Squibb, Gilead Sciences
The following PIM clinical content reviewers, Linda Graham, RN; Jan Hixon, RN; and Trace Hutchison, PharmD, and Gerald Carlson, PhD with CLD Communications,
hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests
related to the content of this CME activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute Institute for Medicine (PIM), Chronic Liver Disease Foundation (CLDF), Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Onyx Pharmaceuticals, Roche Pharmaceuticals, Salix Pharmaceuticals and Vertex Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CLDF, Bayer Healthcare Pharmaceuticals, Bristol Myers Squibb, Gilead Sciences, Onyx Pharmaceuticals, Roche Pharmaceuticals, Salix Pharmaceuticals and Vertex Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Jointly sponsored by Postgraduate Institute for Medicine and the Chronic Liver Disease Foundation
This activity supported by: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences,
Onyx Pharmaceuticals, Roche Pharmaceuticals, Salix Pharmaceuticals and Vertex Pharmaceuticals
